Lobaplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: a 5-year follow-up of a randomized, open-label, phase II trial

PURPOSE: We report the 5-year follow-up findings of a randomized, open-label, phase II trial of lobaplatin-based neoadjuvant chemotherapy plus adjuvant therapy for triple-negative breast cancer (TNBC). PATIENTS AND METHODS: This study included patients aged ⩾18 years with untreated, operable stage I...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Wenting, Wu, Xiujuan, Wang, Shushu, He, Cheng, Zhong, Ling, Tang, Peng, Ren, Lin, Zhang, Ting, Qi, Xiaowei, Zhang, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234826/
https://www.ncbi.nlm.nih.gov/pubmed/35769355
http://dx.doi.org/10.1177/17588359221107111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9234826/
https://www.ncbi.nlm.nih.gov/pubmed/35769355
http://dx.doi.org/10.1177/17588359221107111

Ejemplares similares